GlassScriptPhysician profile
Amr Mohamed
NPI 1306281019
$72,274.52
in general payments reported to CMS, 2019-2025
23 companies · $1,409 in 2025
The $1,409 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $182 · 2020: $1,892 · 2021: $34K · 2022: $24K · 2023: $1,958 · 2024: $9,126 · 2025: $1,409.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $6,000 · Travel and Lodging: $2,455 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,740 · Food and Beverage: $1,197 · Consulting Fee: $1,100.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $6,000.00 |
| Travel and Lodging | $2,454.64 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,740.00 |
| Food and Beverage | $1,197.34 |
| Consulting Fee | $1,100.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ipsen Biopharmaceuticals, INC | $56,483.20 | 2019-2023 | Onivyde, Somatuline Depot |
| Exelixis INC. | $8,782.37 | 2024 | Cabometyx |
| Tersera Therapeutics LLC | $2,917.89 | 2021-2025 | Zoladex, Xermelo |
| Advanced Accelerator Applications | $1,880.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $1,209.18 | 2022-2025 | |
| Tempus Ai, INC | $195.83 | 2024-2025 | Xt Cdx |
| Boston Scientific Corporation | $119.85 | 2022 | |
| Eisai INC. | $115.24 | 2023-2025 | |
| Pfizer INC. | $109.07 | 2024-2025 | |
| Janssen Biotech, INC. | $89.99 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $74.11 | 2023-2025 | Imfinzi |
| Bayer Healthcare Pharmaceuticals INC. | $62.17 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $50.08 | 2023-2025 | Keytruda, Lynparza, Welireg |
| Impulse Dynamics (USA) INC. | $31.92 | 2024 | Optimizer |
| Edwards Lifesciences Corporation | $24.13 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.69 | 2024 | Opdivo |
| Glaxosmithkline, LLC. | $18.24 | 2025 | Jemperli |
| Lilly USA, LLC | $17.72 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $16.46 | 2024 | |
| Beigene USA, INC. | $16.42 | 2022 | |
| Taiho Oncology, INC. | $14.95 | 2023 | |
| Astellas Pharma US INC | $14.31 | 2021 | |
| Puma Biotechnology, INC. | $12.70 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amr Mohamed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.